• Original article (Clinical research) • Previous Articles     Next Articles

Clinical study on the early prediction of the remission rate and survival of patients with recurrent metastatic NSCLC by 18F-FDG PET/CT

XU Hai-yan1, XU Yuan-fan2, YAN Ning-ning1,3, CHEN Bin1, XU Ying-chun4, LIU Jian-jun2,5, ZHANG Feng-chun1,3   

  1. 1.Department of Oncology, Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou 215021； 2.Department of Nuclear Medicine，Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou 215021； 3.Department of Oncology, Ruijin Hospital， Shanghai Jiao Tong University School of Medicine, Shanghai 200025； 4.Department of Oncology, Renji Hospital Shanghai Jiao Tong University School of Medicine, Shanghai 200127； 5.Department of Nuclear Medicine， Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127
  • Online:2015-11-28 Published:2016-01-13
  • Supported by:

    National Natural Science Foundation of China， 81471687； Scientific Research Foundation of Shanghai Municipal Health Bureau， 201440606； Science and Technology Development Project of National Health and Family Planning Commision of China， W2012FZ129

PDF (PC)

1527

Abstract:

Objective  To explore the application value of the 18F-FDG PET/CT for early prediction of the remission rate and survival of recurrent metastatic non-small cell lung cancer (NSCLC). Methods  A total of 24 patients with recurrent or metastatic NSCLC were selected. All patients underwent the PET/CT examination before and after the first cycle of chemotherapy. The differences of SUVmax1, SUVmax2, ΔSUVmax, and the change rate of SUVmax between the objective response (OR) group and non-objective response (non-OR) group were analyzed, as well as the effect of metabolic response on the overall survival (OS). Results  ΔSUVmax of the OR group (2.415±0.266) was significantly higher than that of the non-OR group (0.854±0.316, P=0.001 7). The change rate of SUVmax of the OR group (31.320±0.723) was remarkably higher than that of the non-OR group (9.909±3.592, P<0.001). The survival analysis showed that the overall survival of the OR group was obviously longer than that of the non-OR group (P<0.05). The overall survival of the metabolic response group was significantly longer than that of the non-metabolic response group (P<0.05). The remission response rates of the metabolic response group and non-metabolic response group were 76.92% and 0%, respectively (χ2=13.901, P<0.001). Conclusion  18F-FDG PET/CT is valuable for early prediction of the remission rate and survival of patients with recurrent or metastatic NSCLC and further clinical study and verification are needed.

Key words: PET/CT, NSCLC, metabolic response, response rate